Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Overview of Obsessive-Compulsive Disorder
  • Disease Diagnosis and Symptoms
  • Etiology
  • Epidemiology
• Current Treatments for Obsessive-Compulsive Disorder
  • Treatment Algorithm for Obsessive-Compulsive Disorder
  • FDA-Approved Treatments for Obsessive-Compulsive Disorder
    • Eli Lilly' s Prozac
    • GlaxoSmithKline' s Paxil
    • Pfi zer' s Zoloft
    • Novartis' s Anafranil
  • Drugs Used Off-Label to Treat Obsessive-Compulsive Disorder
    • Forest Laboratories' Lexapro
    • SNRIs
    • Benzodiazepines
    • Atypical Antipsychotics
• 2007 U.S. Market
• Maximizing the Potential of the Obsessive-Compulsive Disorder Market
  • Current Dynamics of the Obsessive-Compulsive Disorder Market
  • Strategies for the Obsessive-Compulsive Disorder Market
    • Pediatric Approval
    • Small Clinical Trials

Tables:

• 1. Agents Commonly Used to Treat Obsessive-Compulsive Disorder
• 2. U.S. Obsessive-Compulsive Disorder Market, 2007
• 3. Agents Approved for Other Indications Being Investigated for Effi cacy in Obsessive-Compulsive Disorder, 2008

Figures:

• 1. Total Prevalent Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007-2017
• 2. Diagnosed and Drug-Treated Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007
• 3. Treatment Algorithm for Obsessive-Compulsive Disorder
• 4. SSRI Action at the Serotonergic Synapse
• 5. Market Share of Leading Companies in the U.S. Obsessive-Compulsive Disorder Market, 2007